整合超声O-RADS与血清指标的卵巢肿块恶性预测列线图模型
本回顾性研究纳入201例良性卵巢肿块患者和136例卵巢癌患者,术前进行超声O-RADS评估并检测CA125和NLR,建立整合US O-RADS与血清指标的列线图模型,模型AUC为0.950(95%CI 0.927-0.973),敏感度94.1%,特异度84.6%,校准曲线和决策曲线分析显示良好拟合和临床净获益。
要点
- US O-RADS联合CA125、NLR构建的列线图模型对卵巢肿块恶性预测具有高诊断准确性(AUC 0.950)。
- 模型敏感度94.1%、特异度84.6%,有助于术前风险分层。
- 决策曲线分析显示在广泛阈值概率范围内具有临床净获益。
诊断标准与关键数值
- 模型AUC为0.950(95%CI 0.927-0.973),敏感度94.1%,特异度84.6%。
- CA125、NLR和US O-RADS在恶性组均高于良性组,均纳入列线图模型。
临床应用与阅片要点
- 术前可结合US O-RADS评分、CA125和NLR列线图评估卵巢肿块恶性风险。
- 模型高敏感度(94.1%)有助于减少恶性病变漏诊。
局限性
- 回顾性研究设计。
- 仅进行内部验证,未进行外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To design a diagnostic nomogram model integrating the Ultrasound Ovarian-Adnexal Reporting and Data System (US O-RADS) and serum indexes for predicting malignancy in patients with ovarian masses.
METHODS: This was a retrospective study including 201 benign ovarian masses patients [median age: 36(29-53)] and 136 ovarian cancer (OC) patients [median age: 53(46-60)]. Before surgical resection, all patients underwent ultrasound examination, and US O-RADS were assessed. Meanwhile, cancer antigen 125 (CA125) and neutrophil to lymphocyte ratio (NLR) were tested. All patients were pathologically diagnosed. The differences in these indexes between two groups were analysed. Meanwhile, ROC curves were firstly graphed to determine their optimal cut-off values. Logistic regression analyses were used to identify CA125, NLR and US O-RADS for OC. Then, the nomogram model was established. Finally, we evaluated the model and performed internal validation.
RESULTS: CA125, NLR and US O-RADS in the malignant group were higher compared to the benign group. These parameters were incorporated to develop a nomogram model with an area under the ROC curve (AUC) of 0.950 (95% confidence interval [CI], 0.927-0.973), 94.1% sensitivity and 84.6% specificity. The calibration curve displayed a satisfactory fitting degree. Meanwhile, Decision curve analysis (DCA) provided a net benefit for a range of threshold probabilities.
CONCLUSIONS: This nomogram model yielded a favourable diagnostic accuracy for predicting malignancy in patients with ovarian masses.
ADVANCES IN KNOWLEDGE: This was the first nomogram model integrating US O-RADS and serum indexes, which showed satisfactory discrimination, calibration abilities and clinical net benefit for predicting malignancy in patients with ovarian masses.
引用
- Gu Y, Zhao L, Yang L, et al. A diagnostic nomogram model integrating the ultrasound ovarian-adnexal reporting and data system and serum indexes for predicting malignancy in patients with ovarian masses. Br J Radiol. 2026. PMID: 42024575. doi:10.1093/bjr/tqag084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。